DUBLIN--(BUSINESS WIRE)-- <\/p>\n
Research and Markets (http:\/\/www.researchandmarkets.com\/research\/h3n97n\/companion_diagnost<\/a>) has announced the addition of the \"Companion Diagnostics in Personalized Medicine and Cancer Therapy\" report to their offering. <\/p>\n Companion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy. This linkage could be important in the therapeutic application and clinical outcome of a drug, such as with personalized medicine for oncology patients. The molecular diagnostics field plays a vital part in personalized medicine and has greatly expanded over the past twenty years, expanding by more than 20% annually compared to most other laboratory procedures. Research will continue to produce an increased understanding of disease processes, and diagnostics manufacturers will continue to expand and refine the technology and automation needed for clinical testing. Companion diagnostics, although smaller at present, is one of the fastest growing segments in the in vitro diagnostic (IVD) market. And while the concept of a drug-diagnostic combination is not new, it has only recently started to generate interest with the move of healthcare towards pharmacogenomics. <\/p>\n This TriMark Publications report examines the use of companion diagnostics in personalized medicine and cancer therapy. The study provides a qualitative and quantitative review of the industry, including cancer biomarker tests, pharmacogenomics tests, recurrence prediction tests, blood-based technologies, proteomics and regulatory trends. Moreover, this analysis profiles the leading companies that are developing and manufacturing companion diagnostics solutions. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included. <\/p>\n Key Topics Covered: <\/p>\n 1. Overview <\/p>\n 2. Companion Diagnostics and Personalized Medicine <\/p>\n 3. Companion Diagnostics: Qualitative and Quantitative Market Analysis <\/p>\n 4. Trends and Overview <\/p>\n 5. Biomarker Tests Co-developed with Cancer Therapeutics as Companion Diagnostics <\/p>\n<\/p>\n Originally posted here: <\/p>\n Research and Markets: Companion Diagnostics in Personalized Medicine and Cancer Therapy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" DUBLIN--(BUSINESS WIRE)-- Research and Markets (http:\/\/www.researchandmarkets.com\/research\/h3n97n\/companion_diagnost<\/a>) has announced the addition of the \"Companion Diagnostics in Personalized Medicine and Cancer Therapy\" report to their offering. Continue reading